Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older
详细信息 查看全文
- 作者：Kate McKeage
- 刊名：Pediatric Drugs
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：18
- 期：1
- 页码：75-81
- 全文大小：486 KB
- 参考文献：1.Abu-Arafeh I, Razak S, Sivaraman B, et al. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088–97.CrossRef PubMed
2.International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.CrossRef
3.Termine C, Ozge A, Antonaci F, et al. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. J Headache Pain. 2011;12(1):25–34.PubMedCentral CrossRef PubMed
4.Anttila P, Metsahonkala L, Sillanpaa M. Long-term trends in the incidence of headache in Finnish school children. Pediatrics. 2006;117:e1197–201.CrossRef PubMed
5.Arruda MA, Bigal ME. Behavioral and emotional symptoms and primary headaches in children: a population-based study. Cephalalgia. 2012;32:1093–100.CrossRef PubMed
6.Kernick D, Reinhold D, Campbell JL. Impact of headache on young people in a school population. Br J Gen Pract. 2009;59:678–81.PubMedCentral CrossRef PubMed
7.O’Brien HL, Kabbouche MA, Kacperski J, et al. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015. doi:10.1007/s11940-014-0326-1 .PubMed
8.Nicholson R. Pediatric migraine treatment: poor adherence to evidence-based acute medication guidelines [abstract no. 89544]. In: 57th Annual Scientific Meeting of the American Headache Society; 2015.
9.Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med. 2002;346:257–70.CrossRef PubMed
10.Evers S. The efficacy of triptans in childhood and adolescent migraine. Curr Pain Headache Rep. 2013;17:342.CrossRef PubMed
11.Rothner AD, Wasiewski W, Winner P, et al. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46:101–9.CrossRef PubMed
12.AstraZeneca. ZOMIG (zolmitriptan nasal spray): prescribing information. 2015. http://www.azpicentral.com/zomig-nasal-spray . Accessed 17 Sep 2015.
13.Spencer CM, Gunasekara NS, Hills C. Zolmitriptan: a review of its use in migraine. Drugs. 1999;58(2):347–74.CrossRef PubMed
14.Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121(2):157–64.PubMedCentral CrossRef PubMed
15.Dixon R, Gillotin C, Gibbens M, et al. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol. 1997;43(3):273–81.PubMedCentral CrossRef PubMed
16.Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997;17(Suppl 18):4–14.PubMed
17.Dixon RM, Meire HB, Evans DH, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia. 1997;17(6):639–46.CrossRef PubMed
18.Wall A, Kagedal M, Berstrom M, et al. Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study. Drugs R D. 2005;6:139–47.CrossRef PubMed
19.Bergstrom M, Yates RA, Wall A, et al. Blood–brain barrier penetration of zolmitriptan: modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn. 2006;33:75–91.CrossRef PubMed
20.Proietti-Cecchini A, Afra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia. 1997;17(8):849–54 (discussion 799).
21.Mercer AJ, Lamb RJ, Rolan PE, et al. Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers. Psychopharmacology (Berl). 1998;140:398–404.CrossRef PubMed
22.Goadsby PJ, Yates R. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006;46:138–49.CrossRef PubMed
23.Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol. 1999;9:35–42.CrossRef PubMed
24.Yates R, Sorensen J, Bergstrom M, et al. Distribution of intranasal 11C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005;25:1103–9.CrossRef PubMed
25.Tepper SJ, Chen S, Reidenbach F, et al. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013;53:62–71.CrossRef PubMed
26.Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol. 2002;42:1237–43.CrossRef PubMed
27.Yates RA, Nairn K, Dixon R, et al. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol. 2002;42:1244–50.CrossRef PubMed
28.Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17(9):653–67.CrossRef PubMed
29.Dowson AJ, Charlesworth BR, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs. 2003;17(11):839–51.CrossRef PubMed
30.Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120(2):390–6.CrossRef PubMed
31.Winner P, Woodruff B, Liss CL, et al. Efficacy and safety of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: the TEENZ study [abstract no. LBP05 plus poster]. In: 57th Annual Scientific Meeting of the American Headache Society. 2015.
32.Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63(12):2215–24.CrossRef PubMed
33.Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx. 2006;3(2):181–91.PubMedCentral CrossRef PubMed - 作者单位：Kate McKeage (1)
1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand - 刊物主题：Pediatrics; Pharmacotherapy; Internal Medicine;
- 出版者：Springer International Publishing
- ISSN：1179-2019
文摘
The intranasal formulation of zolmitriptan, a selective serotonin 5-HT1B/1D agonist, was recently approved by the US Food and Drug Administration for the treatment of acute migraine in pediatric patients 12 years of age or older. This article summarizes the efficacy and tolerability of zolmitriptan (Zomig®) nasal spray (NS) in acute migraine in this patient group. Zolmitriptan NS 5 mg was more effective in relieving headache pain than placebo in two double-blind studies in pediatric patients 12–17 years of age with acute migraine. Furthermore, zolmitriptan NS 2.5 and 5 mg effectively relieved photophobia and phonophobia, and was associated with a faster return to normal daily activities than placebo. Zolmitriptan NS is rapidly absorbed from the nasal mucosa and is associated with a fast onset of action, with one study showing a significant difference versus placebo with regard to headache response 15 min after administration. In both trials, zolmitriptan NS was generally well tolerated, with no serious adverse events. In conclusion, zolmitriptan NS provides rapid, effective and generally well tolerated treatment of acute migraine in pediatric patients 12 years of age or older and may be of particular benefit for those with nausea or not easily able to swallow tablets. The manuscript was reviewed by: K. J. August, Department of Pediatrics, Children’s Mercy Hospital, Kansas City, MO, USA; J. R. Couch, Department of Neurology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; J. Kacperski, Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; A. Pakalnis, Department of Neurology, Nationwide Children’s Hospital, Columbus, OH, USA.